Every rule your marketing answers to.

Warrant reviews your marketing against 3,388 rules from 1,267 regulators across 11 countries. Every flag is cited to its source. Search the full library below.

Coverage includes the FTC, FDA, CFPB, SEC, FINRA, NCUA, FDIC, OCC, NAIC, and regulators from all 50 U.S. states, the European Union, Canada, and more.

Get a free homepage compliance scan

Regulation guides

Treasury / DEA Cannabis Schedule III Rescheduling Pending — Marketing Implications

Marketing that mentions cannabis rescheduling must accurately state the current federal status and Section 280E applicability and must not present proposed rescheduling as final, as federal legalization, or as a certain investment catalyst.

DEA NPRM, Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) (FR Doc. 2024-11137); 21 U.S.C. 812(b)(3), (c) Schedule I(c)(10); 26 U.S.C. 280E; 12 U.S.C. 5536(a)(1)(B); 15 U.S.C. 45(a)(1); DEA notices of Apr. 28, 2026 (FR Doc. 2026-08177, new hearing; 2026-08178, prior notice withdrawn); final rule FR Doc. 2026-08176 (FDA-approved marijuana products to Schedule III)

Browse by category

Browse by jurisdiction

Browse by regulator